Sitemap - 2025 - The Oncology Shot with Timothee Olivier

Aging Out of Evidence: Why Cancer Trials Still Miss Older Adults

How To Study Drugs With Apparent Massive Effect Sizes, Still Using Randomization?

Placebo First, Treatment Later: Is This Fair to Patients With Active Cancer?

An Interview with Professor Rajshekhar Chakraborty: How Should We Care for Patients with High-Risk Smoldering Myeloma?

When the Follow-Up Ends Too Soon: Rethinking Long-Term Benefit of Immunotherapy

Spotting informative censoring with longer follow-ups — the NADINA and NATALEE trials show two different patterns.

Are fears of rising cancer in young adults exaggerated? A live talk with Ade Adamson

The Iceberg Plot: A Visual I Conceived to Differentiate Tumor Biology from Treatment Effect.

Post-ESMO 2025 on Adjuvant CDK4/6 Inhibitors after MonarchE and NATALEE Updates.

Reduce Toxicity and Save Money: The Paper and Website to Bookmark for Alternative Dosing in Oncology!

Solving Racial Inequalities in HLA-Restricted Therapies: Lessons from ESMO 2025.

Oncology “Me-Too” Drugs Compared With Original Drugs in Randomized Clinical Trials

Multiplicity in oncology randomized trials: an approach to the KEYNOTE-B96 trial with a detour via bevacizumab

Adjuvant CDK4/6 Inhibitors Still Under Debate: Preparing for the NATALEE and monarchE Updates at ESMO 2025.

The POTOMAC Trial

Will PSMAddition Deliver?

Let's get ready for ESMO 2025 with the KEYNOTE-905 trial! Does EV-Pembro in perioperative bladder cancer set a new standard of care?

Is optimal treatment duration in cancer mostly arbitrary?

Post-Protocol Care: The Missing Piece in Oncology Trials